Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer

Research output: Contribution to journalArticlepeer-review

Abstract

Tivantinib is a selective, oral, non-ATP-competitive, small molecule inhibitor of the c-Met receptor, tyrosine kinase, which is implicated at different levels of tumor cell migration, invasion, proliferation, and metastasis. Tivantinib has shown antitumor activity in various human tumor cell lines and in xenograft models of human cancers, including non-small-cell lung cancer. Few therapeutic options are available at present for advanced non-small-cell lung cancer, so there is a pressing need for new therapeutic strategies to improve response and survival. Amplification of Met has been reported in more than 20% of lung tumors that have acquired resistance to epidermal growth factor receptor inhibitors, implying that treatment of these tumors with a c-Met inhibitor should overcome resistance. Tivantinib has shown interesting and promising results in advanced non-small-cell lung cancer and appears to be well tolerated, either alone or in combination with other drugs. An interesting additional feature is the ability of the drug to delay development of new metastasis, in agreement with the proposed role of Met in this particular setting.

Original languageEnglish
Pages (from-to)15-20
Number of pages6
JournalCancer Management and Research
Volume5
Issue number1
DOIs
Publication statusPublished - Jan 16 2013

Keywords

  • Biomarkers
  • Met inhibitors
  • Non-small-cell lung cancer
  • Tivantinib

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this